Bulletin n°91
Traitements
-
Combinaison de traitements localisés et systémiques (3)
-
Cet article passe en revue les travaux récents sur les nouvelles stratégies de chimioradiothérapie pour le traitement d'un cancer localement avancé du poumon non à petites cellules
New Strategies in Non–Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease
Clinical Cancer Research, 2011
-
A partir de données issues de 12 essais ayant inclus 1 119 patients, cette étude évalue l'effet de l'amifostine sur la survie de patients ayant reçu une radiothérapie
Effect of Amifostine on Survival Among Patients Treated With Radiotherapy: A Meta-Analysis of Individual Patient Data
Journal of Clinical Oncology, 2011
-
File
Mené sur 1 861 patients atteints d'un cancer rectal résécable (durée médiane de suivi: 12 ans), cet essai évalue la combinaison d'une radiothérapie pré-opératoire et d'une excision totale du mésorectum
-
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial
2024
-
Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma—Less Is More
2024
-
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial
2024
-
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial
2024
-
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
The Lancet Oncology, 2024
-
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
The Lancet, 2024
-
Immunotherapy plus chemoradiotherapy in cervical cancer management
The Lancet, 2024
-
What Is the Best Local Therapy for HCC?: It Actually Matters More How They All Work Together
2023
-
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma
2023
-
Who does not benefit from whole-breast radiotherapy and how to find them?
The Lancet Oncology, 2023
-
Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer
The Lancet Oncology, 2023
-
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
The Lancet Oncology, 2023
-
Optimising therapy and avoiding overtreatment in breast cancer
The Lancet Oncology, 2023
-
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
The Lancet Oncology, 2023
-
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
The Lancet Oncology, 2023
-
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
The Lancet Gastroenterology & Hepatology, 2023
-
CROSS versus modified MAGIC or FLOT in oesophageal and gastro-oesophageal junction adenocarcinoma
The Lancet Gastroenterology & Hepatology, 2023
-
Risk Factors for Progression and Toxic Effects After Preoperative Stereotactic Radiosurgery for Patients With Resected Brain Metastases
JAMA Oncology, 2023
-
The Emerging Paradigm of Preoperative Stereotactic Radiosurgery for Resectable Brain Metastases
JAMA Oncology, 2023
-
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial
The Lancet Oncology, 2023
-
Randomised controlled trials are feasible in anaplastic thyroid cancer
The Lancet Oncology, 2023
-
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
The Lancet Oncology, 2022
-
Adding PD-1 inhibition to chemoradiotherapy for oesophageal cancer
The Lancet Oncology, 2022
-
Association of Breast-Conserving Therapy With Measures of Long-term Quality of Life Compared With Mastectomy and Reconstruction
JAMA Surgery, 2022
-
Multifocal Intrahepatic Cholangiocarcinoma and Operative Management of Inoperable Disease
JAMA Surgery, 2022
-
Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma
JAMA Surgery, 2022
-
-
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial
JAMA Oncology, 2022
-
Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction
JAMA Surgery, 2022
-
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer
JAMA Surgery, 2022
-
Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial
JAMA Surgery, 2022
-
Breast surgery after neoadjuvant chemotherapy: time for a change?
The Lancet Oncology, 2022
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
The Lancet Oncology, 2022
-
Forging a Path for Metformin Use in Inoperable Locally Advanced Non–Small Cell Lung Cancer
JAMA Oncology, 2021
-
Laparoscopic pancreatoduodenectomy: extensive learning curve, marginal benefits
The Lancet Gastroenterology & Hepatology, 2021
-
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
The Lancet Gastroenterology & Hepatology, 2021
-
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial
JAMA Oncology, 2021
-
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial
JAMA Oncology, 2021
-
Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial
The Lancet Oncology, 2021
-
Next generation platinum salt in nasopharygeal carcinoma
The Lancet Oncology, 2021
-
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis
JAMA Network Open, 2020
-
Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way
JAMA Network Open, 2020
-
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
The Lancet Haematology, 2020
-
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure"
The Lancet Haematology, 2020
-
Improving Treatment for Advanced Prostate Cancer
New England Journal of Medicine, 2019
-
Fusion gene-oriented precision medicine in soft tissue sarcoma
The Lancet Oncology, 2019
-
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
New England Journal of Medicine, 2019
-
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial
The Lancet Oncology, 2019
-
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma
Journal of Clinical Oncology, 2016
-
-
-
Traitements localisés : applications cliniques (1)
-
Cet article passe en revue les travaux récents sur la tolérance du système nerveux central aux doses de rayonnements produits par une radiochirurgie stéréotaxique et une radiothérapie stéréotaxique hypofractionnée
Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: Normal tissue dose constraints of the central nervous system
Cancer Treatment Reviews, 2011
-
-
Traitements systémiques : applications cliniques (2)
-
A partir de données portant sur 3 173 patients suédois traités pour une leucémie myéloïde chronique entre 1973 et 2008, cette étude évalue l'impact de l'imatinib sur la survie relative à partir de 2001
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Journal of Clinical Oncology, 2011
-
Cet article passe en revue les travaux récents sur les thérapies ciblées dans le cancer avancé du poumon non à petites cellules
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Cancer Treatment Reviews, 2011
-
-
Traitements systémiques : découverte et développement (7)
-
Mené sur 45 patients présentant des tumeurs solides de stade avancé, cet essai de phase I évalue un inhibiteur oral des tyrosines kinases de la famille des récepteurs HER
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
Annals of Oncology, 2011
-
Cet article passe en revue les nouvelles approches thérapeutiques dans la prise en charge d'un cancer de la prostate métastatique et résistant à la castration
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
2011
-
Cette étude montre que le gène BCL6 joue un rôle essentiel dans l'apparition d'une résistance à un inhibiteur de l'activité tyrosine kinase de BCR-ABL1
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition
Nature, 2011
-
Cette étude montre que la tyrosine kinase LMTK3 constitue une nouvelle cible thérapeutique potentielle dans les cancers du sein
Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer
Nature Medicine, 2011
-
Cet article passe en revue les perspectives offertes par l'induction ou l'inhibition de l'autophagie dans le traitement des cancers
Autophagy as a target for anticancer therapy
Nature Reviews Clinical Oncology, 2011
-
Cet article passe en revue les perspectives offertes par le ciblage des kinases Raf dans le traitement des mélanomes et d'autres types de cancer
-
Cet article passe en revue les perspectives thérapeutiques offertes par les connaissances sur le rôle de l'interleukine-6 dans la formation de métastases osseuses
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies
2011
-